Youjiang Medical University Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2015
NCT02434614
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Affiliated Hospital of Youjiang Medical University for Nationalities

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (2 trials)

docetaxel (taxotere) (1 trial)

fluorouracil (efudex) (1 trial)

Drugs in Other Trials (2)

gemcitabine (gemzar) (1 trial)

nimotuzumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Nasopharyngeal Carcinoma (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 5